Volume 22, Number 11—November 2016
Dispatch
Novel LevofloxacinResistant MultidrugResistant Streptococcus pneumoniae Serotype 11A Isolates, South Korea
Table 2
Strain 
MIC, μg/mL (resistance) 


LEV 
OFL 
CIP† 
PEN 
AMX 
CRO 
MER 
ERY 
CLI 
VAN 
LZD 
TET 
TIG† 

HM646  16 (R)  32 (R)  32  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM669  16 (R)  32 (R)  32  >16 (R)  >16 (R)  >16 (R)  8 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM683  8 (R)  16 (R)  16  4 (I)  2 (S)  2 (I)  1 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM688  16 (R)  32 (R)  32  >16 (R)  >16 (R)  >16 (R)  8 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM730  8 (R)  16 (R)  8  4 (I)  2 (S)  2 (I)  0.5 (I)  >16 (R)  >16 (R)  0.5 (S)  0.5 (S)  >16 (R)  0.03 
HM762  32 (R)  64 (R)  32  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  0.5 (S)  >16 (R)  0.015 
HM781  16 (R)  32 (R)  16  16 (R)  16 (R)  >16 (R)  8 (R)  >16 (R)  >16 (R)  0.5 (S)  0.5 (S)  16 (R)  0.03 
HM787  16 (R)  32 (R)  64  16 (R)  16 (R)  >16 (R)  8 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM809  16 (R)  32 (R)  64  16 (R)  >16 (R)  >16 (R)  4 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM854  8 (R)  16 (R)  16  0.06 (S)  0.06 (S)  0.5 (S)  <0.015 (S)  8 (R)  0.06 (S)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM878  16 (R)  32 (R)  32  16 (R)  >16 (R)  >16 (R)  8 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  4 (R)  0.03 
HM953  16 (R)  32 (R)  64  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM970  32 (R)  64 (R)  32  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM1017  64 (R)  128 (R)  64  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
HM1050  32 (R)  64 (R)  64  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  0.5 (S)  0.03 
HM1055  16 (R)  32 (R)  128  >16 (R)  >16 (R)  >16 (R)  16 (R)  >16 (R)  >16 (R)  0.5 (S)  1 (S)  >16 (R)  0.03 
*AMX, amoxicillin; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; I, intermediate; LEV, levofloxacin; LZD, linezolid; MER, meropenem; OFL, ofloxacin; PEN, penicillin; R, resistant; S, susceptible; TET, tetracycline; TIG, tigecycline; VAN, vancomycin.
†No susceptibility breakpoints are established for ciprofloxacin and tigecycline.